A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
118actual
Sites
22
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-10 | actual | When the study began enrolling |
| Primary completion | 2025-06-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Combination product: Intervention: AS MDI — also filed as Albuterol Sulfate metered dose inhaler [AS MDI] - PT007)
- Combination product: Intervention: Ventolin Evohaler
- Combination product: Intervention: Placebo matching AS MDI
Primary outcome
what the primary-completion date above is the date OFChange from baseline in FEV1 AUC 0-6 hours
measured 0 to 6 hours (Spirometry will be obtained 60 and 30 minutes pre-dose and 5, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes post-dose)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed